Abstract

Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

Original languageEnglish
JournalFuture Oncology
DOIs
Publication statusPublished - 2019

Fingerprint

Lung Neoplasms
Ligands
Non-Small Cell Lung Carcinoma
Antibodies, Monoclonal, Humanized
Biological Factors
Platinum
Oncogenes
Radiotherapy
Randomized Controlled Trials
pembrolizumab

Cite this

@article{4f792b88da834efe9a9241a89865040a,
title = "Pembrolizumab in lung cancer: current evidence and future perspectives",
abstract = "Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1{\%} (KEYNOTE-010), in first-line setting PD-L1 ≥50{\%} (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.",
author = "Giuliano Palumbo and Guido Carillio and Anna Manzo and Agnese Montanino and Vincenzo Sforza and Raffaele Costanzo and Claudia Sandomenico and Manna, {Carmine La} and Luca, {Giuseppe De} and Piccirillo, {Maria Carmela} and Gennaro Daniele and Cecio, {Rossella De} and Gerardo Botti and Giuseppe Totaro and Paolo Muto and Carmine Picone and Giovanna Esposito and Nicola Normanno and Alessandro Morabito",
year = "2019",
doi = "10.2217/fon-2019-0073",
language = "English",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Pembrolizumab in lung cancer

T2 - current evidence and future perspectives

AU - Palumbo, Giuliano

AU - Carillio, Guido

AU - Manzo, Anna

AU - Montanino, Agnese

AU - Sforza, Vincenzo

AU - Costanzo, Raffaele

AU - Sandomenico, Claudia

AU - Manna, Carmine La

AU - Luca, Giuseppe De

AU - Piccirillo, Maria Carmela

AU - Daniele, Gennaro

AU - Cecio, Rossella De

AU - Botti, Gerardo

AU - Totaro, Giuseppe

AU - Muto, Paolo

AU - Picone, Carmine

AU - Esposito, Giovanna

AU - Normanno, Nicola

AU - Morabito, Alessandro

PY - 2019

Y1 - 2019

N2 - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

AB - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

U2 - 10.2217/fon-2019-0073

DO - 10.2217/fon-2019-0073

M3 - Article

C2 - 31432705

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -